Loading
Cancer Research and Treatments · Journal article
Pakistan Veterinary Journal · July 16, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an early-stage characterization of a novel lytic bacteriophage targeting multidrug-resistant bovine MRSA, isolated from dairy farm wastewater. The phage demonstrated dose-dependent protection in a mouse lethal infection model and reduced MRSA viability in dairy product matrices under laboratory conditions. The work provides foundational virology and in vitro/in vivo data suitable for hypothesis generation and future phage-therapy development, but lacks clinical evidence or efficacy in the natural host (cattle).
Phage isolation and characterization study with mouse infection model. Laboratory mice; multidrug-resistant bovine-derived MRSA isolated strain; no cattle or human participants.. Intervention: Phage vB_SauL_SHZU01 at doses of 10^7–10^8 PFU administered in mouse lethal infection model.. Compared with: Untreated MRSA infection (lethal challenge); no phage-therapy comparator arms or other therapeutic controls mentioned.. Not stated in the source text..
Phage vB_SauL_SHZU01 is lytic with 30-minute latent period and optimal MOI of 0.1; genome is 44,364 bp linear dsDNA with 33.6% GC content and no antibiotic resistance genes detected. In mouse infection model, 10^8–10^10 CFU of S. aureus strain caused 100% mortality; doses ≤10^7 CFU were nonlethal. Phage therapy was dose-dependent: protection at ≥10^7 PFU, 100% mouse survival at 10^8 PFU, with tissue repair of liver, spleen, and kidney damage.
Dairy product application assessed only in vitro; no field trials or proof of safety/efficacy in food products. In mouse infection model, 10^8–10^10 CFU of S. aureus strain caused 100% mortality; doses ≤10^7 CFU were nonlethal.
This work is preclinical and does not yet support clinical use. It provides a foundation for phage-therapy research and suggests the phage may have utility for biological control in livestock farming, but efficacy in the target species (cattle) and safety/efficacy in humans remain to be demonstrated.
Early-phase characterization of a novel bacteriophage with in vivo proof-of-concept in a mouse infection model, but no clinical efficacy data, no human studies, and application to dairy products shown only in vitro.
As stated by the source record.
Quoted from the source exactly as published.
This work is preclinical and does not yet support clinical use. It provides a foundation for phage-therapy research and suggests the phage may have utility for biological control in livestock farming, but efficacy in the target species (cattle) and safety/efficacy in humans remain to be demonstrated.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The abuse of antibiotics in the livestock and poultry industry has accelerated the spread of bovine-derived methicillin-resistant Staphylococcus aureus (MRSA), which not only endangers cattle health and reduces breeding efficiency but also threatens public health through the food chain.In this study, a lytic phage vB_SauL_SHZU01 targeting multidrug-resistant bovine-derived MRSA was isolated from dairy farm wastewater and systematically characterized.The phage had an icosahedral head and a long tail, belonging to the family Siphoviridae.It had an optimal multiplicity of infection (MOI) of 0.1, a short latent period of only 30 minutes, and strong infectivity.Its titer peaked at 37℃; it tolerated temperatures up to 50℃, remained infectious within pH 6-10, and showed time-dependent sensitivity to UV radiation.Whole-genome sequencing revealed that the phage contains a linear double-stranded DNA genome of 44,364 bp with a GC content of 33.6%.No antibiotic resistance genes were detected, but one anti-CRISPR proteincoding region was identified.Mouse experiments showed that 10 8 -10 10 CFU of this S. aureus strain caused 100% mortality in mice, while doses ≤10 7 CFU were nonlethal.The therapeutic effect of phage vB_SauL_SHZU01 was dose-dependent: it provided protection at ≥10 7 PFU, achieved 100% mouse survival at 10 8 PFU, and repaired liver, spleen, and kidney tissue damage caused by MRSA infection.In dairy product matrices, the phage effectively reduced the viable count of MRSA, and its antibacterial activity was synergistically regulated by temperature, matrix type, and MOI.In summary, phage vB_SauL_SHZU01 displays excellent lytic activity against multidrug-resistant bovine-derived MRSA.Systematic research on this phage provides a basis for understanding phage-host interactions and optimizing phage therapy, lays a technical foundation for the biological control of drug-resistant bacteria in livestock and poultry farming, and safeguards the safety of animal products and public health.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.